3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Recurrence
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Dexamethasone
16
daratumumab
9
Bortezomib
9
Lenalidomide
6
pomalidomide
4
carfilzomib
4
isatuximab
3
trametinib
2
selinexor
2
dabrafenib
2
Thalidomide
2
Prednisone
2
Melphalan
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
talquetamab
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
montelukast
1
melflufen
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
darlin protein, Dictyostelium
1
copanlisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Multiple Myeloma
×
selinexor
×
Clear all
NCT03110562
2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3
Completed
402 enrolled
22 charts
1 FDA
NCT02336815
2023-01-26
STORM
Karyopharm Therapeutics Inc
Phase 2
Completed
202 enrolled
30 charts
1 FDA